We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Demonstrates Newly Launched DxA 5000 Fit Workflow Automation System at MEDLAB Middle East

By LabMedica International staff writers
Posted on 25 Jan 2022
Print article
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter (Brea, CA, USA) displayed its recently launched DxA 5000 Fit workflow-automation system at the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre.

The clinical laboratory has gone through trial by fire in 2020, where total testing was 245% of baseline volumes, with ~55% being SARS-CoV-2 molecular tests. Despite vaccines, many industry players suggest SARS-CoV-2 testing volumes won't be impacted in the near term, and the demand for COVID-19-related testing will continue through 2021 and potentially into 2022. This means that testing-volume pressure on labs is going to continue. Labs of all sizes are facing the same challenges: shortage of laboratory technologists and technicians, historic financial pressures on hospitals and health systems, and physically and mentally exhausted laboratory professionals – a pre-pandemic problem that has since been exacerbated. However, the TLA solutions that cater to labs processing high-sample volumes are out of reach for smaller volume labs due to space requirements and infrastructure constraints.

Designed to fit into medium-sized labs that run fewer than 5,000 tests a day, the DxA 5000 Fit allows mid-sized labs to enjoy the same benefits as larger-volume labs. The DxA 5000 Fit is an automation system comprising an integrated input/output module - which can be combined with a coagulation and centrifugation - connect clinical chemistry, immunoassay and hematology instruments. The DxA 5000 Fit automation system delivers a unique combination of rapid and consistent turnaround time along with the industry’s most comprehensive pre-analytical sample quality assessment. It delivers significant efficiency gains by joining automated pre- and post-analytical sample processing with connected hematology, chemistry and immunoassay analyzers. The DxA 5000 Fit drives speed and accuracy, all while maintaining a small footprint. It is designed to automate up to 80% of the manual steps associated with processing a patient sample, allowing labs to keep their focus on what matters most: patient care.

Related Links:
Beckman Coulter

Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
Automatic Photometer
JOLLY 103
New
Gold Supplier
NT-proBNP Quantitative Antigen Test
NT-proBNP-CHECK-1
New
3-Part Diff Hematology Analyzer
DLB3

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.